As a novel treatment for heart failure coming into a marketplace that had seen little innovation in recent years, with a proven effect on morbidity and mortality, Entresto should have been a groundbreaking US launch in 2015 for Novartis AG – a region where nearly 5 million people are currently living with congestive heart failure (CHF) and approximately 550,000 new cases are diagnosed each year. But the drug suffered a slower-than-expected start in its biggest market and missed out on sales targets in 2016 despite Novartis introducing new value-based reimbursement methods to tempt US payers.
In light of these unusual circumstances, Scrip has taken a look back at Entresto's story to piece together why a...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
